Avid­i­ty to raise $400M; Sato pays Ar­cutis $25M up­front to li­cense top­i­cal rof­lu­mi­last in Japan

Plus, news about Xen­cor, Ot­su­ka, Type­writer Ther­a­peu­tics, Cas­sa­va Sci­ences, En­ver­ic Bio­sciences, Viking Ther­a­peu­tics and Janux Ther­a­peu­tics:

Next up in the PIPE bo­nan­za: RNA com­pa­ny Avid­i­ty Bio­sciences ex­pects to raise $400 mil­lion from sell­ing stock to more than nine pri­vate in­vestors, RA Cap­i­tal, RTW In­vest­ments and Far­al­lon. Sev­er­al biotech com­pa­nies have raised mon­ey via pri­vate in­vest­ment in pub­lic eq­ui­ty this week. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER